Silver Book Fact

Slowing the Progress of Parkinson’s Disease Would Save Money

Fact image

Johnson S, Diener M, Kaltenboeck A, Birnbaum H, et al. An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States. Mov Disorders. 2013; 28(3). https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.25328

Reference

Title
An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States
Publication
Mov Disorders
Publication Date
2013
Authors
Johnson S, Diener M, Kaltenboeck A, Birnbaum H, et al.
Volume & Issue
Volume 28, Issue 3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Impact of Slowed Progression on Severe Stage, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • Research shows that use of donepezil leads to a 4-fold increase in drug costs; however, it significantly lowers overall medical costs, reducing medical treatment and prescription drug costs by $3,891…  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • A treatment that delayed the age of onset of Alzheimer’s disease by five years would reduce the proportion of Americans age 65 and older with the disease from 10% to…